ENDRA Life Sciences Inc. (NDRA) Company Analysis

Company Overview

ENDRA Life Sciences Inc. is a medical technology company focused on developing imaging solutions to enhance the capabilities of clinical diagnostic ultrasound. The company is known for its Thermo-Acoustic Enhanced Ultrasound (TAEUS®) technology, which aims to provide non-invasive methods for assessing liver health and other tissue characteristics.

Corporate Structure

As of the latest available data, specific employee count details for ENDRA Life Sciences are not disclosed. The company is managed by a team with experience in medical technology and imaging.

Recent Developments

• Stock Performance: As of April 29, 2025, ENDRA's stock price is $5.6995, reflecting a price increase of 32.55% with a trading volume of 156,818 shares on the NASDAQ under the ticker NDRA.
• Reverse Stock Split: On August 16, 2024, ENDRA announced a 1-for-50 reverse stock split effective August 20, 2024, aimed at improving the stock's marketability.
• Regulatory Compliance: The company operates under a Quality Management System compliant with ISO 13485:2016, ensuring adherence to international standards for medical devices.

Financial Analysis

Key Financial Metrics

• Market Capitalization: Approximately $3.37 million.
• Net Income: For the trailing twelve months (TTM), ENDRA reported a net loss of $11.51 million.
• Earnings Per Share (EPS): The diluted EPS is -$56.94.
• Cash Position: The company holds approximately $3.23 million in cash.
• Total Debt to Equity Ratio: 29.45%, indicating a moderate level of debt relative to equity.

Strategic Initiatives

ENDRA is focused on expanding its TAEUS® technology beyond liver diagnostics to include applications in tissue temperature monitoring and vascular imaging. The company is also exploring partnerships to enhance its market reach and operational capabilities.

Market Position and Industry Context

ENDRA operates within the healthcare equipment and supplies industry, specifically targeting the diagnostic imaging sector. The company faces competition from established players in medical imaging, but its focus on non-invasive diagnostics addresses a need for effective diagnostic tools in the context of liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

TL;DR

As of April 29, 2025, ENDRA Life Sciences Inc. (NDRA) trades at $5.6995, up 32.55%. The company executed a 1-for-50 reverse stock split on August 20, 2024. ENDRA reported a net loss of $11.51 million and holds $3.23 million in cash. The firm is advancing its TAEUS® technology for liver diagnostics and exploring additional applications. ENDRA's market capitalization is approximately $3.37 million, with a total debt to equity ratio of 29.45%.